Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 11/20 | 0.65 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1196361 | 1.00 | PTGS1 (0.65) | PTGS1NR1H3PTPN1MMP3MMP9 | |
| SCHEMBL267688 | 0.88 | PTGS1 (0.70) | PTGS1NR1H3PTPN1 | |
| SCHEMBL261637 | 0.88 | PTGS1 (0.69) | PTGS1NR1H3PTPN1 | |
| SCHEMBL267942 | 0.88 | PTGS1 (0.69) | PTGS1NR1H3PTPN1 | |
| SCHEMBL267126 | 0.87 | PTGS1 (0.68) | PTGS1NR1H3PTPN1 | |
| SCHEMBL263520 | 0.85 | PTGS1 (0.68) | PTGS1NR1H3PTPN1 | |
| SCHEMBL266878 | 0.85 | PTGS1 (0.68) | PTGS1NR1H3PTPN1 | |
| SCHEMBL12450160 | 0.85 | PTGS1 (0.70) | PTGS1NR1H3PTPN1 | |
| SCHEMBL263207 | 0.85 | PTGS1 (0.70) | PTGS1NR1H3PTPN1 | |
| SCHEMBL267198 | 0.84 | PTGS1 (0.67) | PTGS1NR1H3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8133915-B2 | Interleukin-1 and tumor necrosis factor-α modulators; syntheses of such modulators and methods of using such modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7893299-B2 | Acanthoic amide derivatives; inflammation, cancer, cachexia, cardiovascular disease, infections, diabetes, otitis media, sinusitis, transplant rejection | NEREUS PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | HENSLER, MARY | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | PTGS1 20/4885NR1H3 3538/4885PTPN1 2008/4885 |
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | PTGS1 20/4885NR1H3 3538/4885PTPN1 2008/4885 |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | IL1A, IL1B, TNF | PTGS1 20/4885NR1H3 3538/4885PTPN1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.